真实世界多支病变患者中CABG较新一代支架PCI具中期生存优势
该回顾性研究纳入英国Harefield医院2007至2015年6383例多支病变(含左主干病变)患者,比较CABG与新一代药物洗脱支架PCI的中期全因死亡率。结果显示CABG组5年估计生存率88%高于PCI组78.3%,校正后PCI相对CABG的死亡风险比1.74,倾向性匹配后为2.18。
要点
- 真实世界多支病变患者中CABG中期生存优于新一代支架PCI
- CABG组5年估计生存率88%,PCI组78.3%
- 倾向性匹配后PCI全因死亡校正HR为2.18
核心结论
- 在真实世界多支病变患者中,CABG与新一代药物洗脱支架PCI相比与中期生存率提高相关。
研究设计与样本
- 回顾性分析纳入英国Harefield医院2007至2015年所有连续多支病变接受CABG或第二/三代药物洗脱支架PCI的患者。
- 共纳入6383例患者,CABG组4230例,PCI组2153例,平均随访3.3年。
- 血运重建方式基于心脏团队讨论,采用Cox回归和倾向性匹配分析。
主要发现
- CABG组平均年龄66.4±10岁,PCI组65.3±12.1岁(P<0.001)。
- CABG组女性比例18.5%低于PCI组20.5%(P=0.026)。
- CABG组5年估计生存率88%高于PCI组78.3%(Plog-rank<0.001)。
- 校正后PCI相对CABG的全因死亡风险比HR为1.74(95%CI 1.41-2.16;P<0.001)。
- 倾向性匹配各组653例,PCI全因死亡校正HR为2.18(95%CI 1.54-3.1;P<0.001)。
临床怎么用
- 心脏团队讨论多支病变血运重建策略时,可将CABG的中期生存优势纳入考量。
局限性
- 为单中心回顾性分析,血运重建方式非随机分配。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The intermediate-term all-cause mortality rate of real-world patients with multivessel disease (MVD) treated with percutaneous coronary intervention (PCI) with new-generation drug-eluting stents or coronary artery bypass grafting (CABG) remains unknown. We sought to compare the intermediate-term all-cause mortality rates of real-world patients with MVD including left main stem disease, treated with CABG or PCI. METHODS: All consecutive all-comer patients with MVD undergoing CABG or PCI with second/third generation drug-eluting stents from 2007 to 2015 in Harefield Hospital, UK were included in this study. The revascularization modality was based on heart team discussions. Primary outcome was all-cause mortality. Mean follow-up of the study was 3.3 years. Cox regression analysis and propensity matching were used. RESULTS: Of 6383 patients with MVD, 4230 underwent CABG, whereas 2153 had PCI with new-generation stents. In the CABG group, the mean age was 66.4 ± 10 years, whereas in the PCI group it was 65.3 ± 12.1 years (P < 0.001). Fewer female patients with MVD were treated with CABG than were treated with PCI (18.5% vs 20.5%; P = 0.026). There was a higher 5-year estimated survival rate among patients having CABG (88% vs 78.3%; Plog-rank < 0.001). The adjusted hazard ratio (HR) for PCI over CABG was 1.74 [95% confidence interval (CI) 1.41-2.16; P < 0.001]. A total of 653 patients having CABG and 653 having PCI were included in the propensity-matched groups. At mean follow-up, PCI was associated with a higher adjusted HR for all-cause mortality (2.18, 95% CI 1.54-3.1; P < 0.001). CONCLUSIONS: In this contemporary cohort of real-world patients with MVD, CABG was associated with increased intermediate-term survival compared to PCI with new-generation drug-eluting stents.
引用
- Panoulas VF, Ilsley CJ, Kalogeras K, et al. Coronary artery bypass confers intermediate-term survival benefit over percutaneous coronary intervention with new-generation stents in real-world patients with multivessel coronary artery disease, including left main disease: a retrospective analysis of 6383 patients. Eur J Cardiothorac Surg. 2019. PMID: 31079151. doi:10.1093/ejcts/ezz142
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。